MTM Laboratories has developed a proprietary technological platform that has identified a novel biomarker that serves for the early detection of cervical cancer.
Browsing: Diagnostics Techreport
Neo Matrix is a medical devices company that has developed a novel diagnostic test to determine breast cancer risk. The company’s test uses breast fluid to analyze the presence of normal, pre-malignant and malignant cells. Unlike traditional tests that detect cell tumor lumps in the breast when cancer has advanced into a mature state, this test can detect cancer risk years before tumor build up. The test is a non-invasive, 5 minute procedure that is fully automated and can be used in busy primary care settings, yet still provides doctors with advanced diagnostic results. Novel diagnostics that can identify the…
Cermed Corporation is a medical devices company that has developed an apparatus for advanced diagnostic analysis of cervical tissue, which serves as a routine screening test for women’s cervical cancer. This unique cervical sampling device is able to achieve a 360 degree collection of the entire cervix thereby enhancing the sampling quality and its diagnostic value. This device is poised to replace the traditional Pap smear which is currently used for women’s cervical screening. Advanced techniques for analyzing cervical tissue is critical for the early diagnosis and successful treatment of cervical cancer, the third most common cancer in women.
Provista Diagnostics, Inc., a Delaware company, is a privately held molecular diagnostics company offering diagnostic testing and reference clinical laboratory services tot he pharmaceutical and biotechnology industries. Additionally, the company is focused on developing and commercializing its own proprietary diagnostic, prognostic and predictive tests for cancers affecting women through its dtectDx platform. Provista develops and commercializes breakthrough, easy to administer blood-based diagnostic tests for early oncology-related disease state recognition and detection purposes. The Company’s focus is on oncology-related diagnostics where a significantly high, unmet clinical need for such testing products exist. The laboratory services, such as biomarker research and evaluation,…
Exosome Diagnostics is a specialized bio-pharmaceutical company that develops a unique kind of genetic-based diagnostic tests. The company’s technological platform isolates from the blood micro-vesicles produced by cells, and then analyze the genetic material in the vesicles, which is representative of the cells they were made from. Certain cells, such as cancer cells, contain a genetic signature and therefore isolation of vesicles containing this genetic material is indicative of the disease. In particular, cancer cells have been shown to produce a large amount of micro-vesicles (or exosomes) and therefore this technology can serve to identify hard to detect cancer cases.…
Seno Medical is a company focused on cancer using its new patented opto-acoustic technology. This new imaging modality combines the use of light in and sound out to uniquely obtain the hallmark indicators of cancer (angiogenesis and oxygen saturation) within the lesion. Seno’s first human (clinical) application will be used as an adjunct to mammogram screening in the early detection of breast cancer. Seno’s technology will be able to detect the lesion earlier and determine whether it is malignant or benign. Seno’s technology will also be able to provide a higher image contrast resolution. Opto-acoustic technology is the first new…